AskAt received a communication under Rule 71(3) EPC dated June 26, 2025 from the European Patent Office, with which the grant of the European patent is proposed. The notice was issued in connection with European Patent Application No. 21891958.7 (Filing Date: November 11, 2021) for a salt and crystal forms patent for its CB2 agonist, AAT-730. In addition to Europe, salt and crystal forms patents have also been granted in Australia, Brazil, Canada, China, Israel, Japan, Korea, Mexico, New Zealand, and the U.S.